Influenza: Reducing Complications in High-risk Patients Through Advanced Treatment Options

THE 2020 AMERICAN ACADEMY OF ALLERGY, ASTHMA & IMMUNOLOGY (AAAAI) ANNUAL MEETING HAS BEEN CANCELED IN RESPONSE TO THE COVID-19 PANDEMIC.DUE TO THIS CANCELLATION, ALL ANCILLARY EVENTS, INCLUDING THIS EVENT WILL NO LONGER TAKE PLACE. WE WOULD LIKE TO THANK YOU FOR YOUR UNDERSTANDING AND INVITE YOU TO CHECK OUR ORGANIZER PAGE FOR FUTURE CME ACTIVITIES RELATED TO THIS TOPIC: http://vindicocme.eventbrite.com/ [http://vindicocme.eventbrite.com/].  ------------------------- ACTIVITY CHAIR PAUL G. AUWAERTER, MD, MBA, FIDSA Sherrilyn and Ken Fisher Professor of Medicine Clinical Director, Division of Infectious Diseases Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases Johns Hopkins University School of Medicine_ Baltimore, MD_ FACULTY ROY F. CHEMALY, MD, MPH, FIDSA, FACP Professor of Medicine Director, Clinical Virology Research Director, Infection Control Section Department of ID/IC/EH University of Texas MD Anderson Cancer Center_ Houston, TX_ JOHN J. RUSSELL, MD Clinical Professor of Family and Community Medicine Thomas Jefferson University Sidney Kimmel School of Medicine _Philadelphia, PA_ Chair, Department of Family Medicine Program Director, Family Medicine Residency Abington – Jefferson Health _Abington, PA_ ------------------------- OVERVIEW Although the impact of influenza varies, it places a substantial burden every year on the health of people in the United States. The Centers for Disease Control and Prevention estimates that influenza has caused between 9.2 million and 35.6 million illnesses, between 140,000 and 710,000 hospitalizations, and between 12,000 and 56,000 deaths annually since 2010. Most hospitalizations and deaths occur in patients who are at high risk for developing complications, including immunocompromised individuals and those with preexisting respiratory conditions, such as asthma or chronic obstructive pulmonary disease. To better manage influenza in high-risk patient populations, clinicians must keep apprised of new information regarding the timely diagnosis and treatment of influenza as well as be equipped to compare the efficacy and safety of available antiviral therapies for prophylaxis and treatment. In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using case-based examples, experts will demonstrate approaches for selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications. ------------------------- AGENDA 6:30 PM REGISTRATION AND DINNER 7:00 PM INTRODUCTION AND PRETEST_ Paul G. Auwaerter, MD, MBA, FIDSA_ 7:05 PM INFLUENZA MANAGEMENT: WHAT’S NEW IN 2020? _Paul G. Auwaerter, MD, MBA, FIDSA_ 7:35 PM Challenging Case 1: Diagnosing and Treating Flu in the Nursing Home Patient With COPD _John J. Russell, MD _ 7:50 PM Challenging Case 2: 13-Year-Old Asthmatic Patient With Symptoms of Flu _John J. Russell, MD_ 8:05 PM Challenging Case 3: Managing Flu in an Immunocompromised Patient _Roy F. Chemaly, MD, MPH, FIDSA, FACP _ 8:20 PM POSTTEST 8:25 PM QUESTION AND ANSWER 8:30 PM Conclusion ------------------------- LEARNING OBJECTIVES Upon successful completion of this activity, participants should be better able to: * Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions. * Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others. * Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications. ------------------------- TARGET AUDIENCE The intended audience for this activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza. ------------------------- This program is not sponsored or programmed by the AAAAI. This non-CME educational program is provided by Vindico Medical Education. This activity is supported by an educational grant from Genentech, Inc. This educational program has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME). This live activity is not approved for _AMA PRA Category 1 Credit(s)_™. In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their RELEVANT FINANCIAL RELATIONSHIPS. Relevant financial relationships will be disclosed to the activity audience. Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee.